Technical Analysis for SBTX - Silverback Therapeutics, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
![]() |
48.32 | -2.93% | -1.46 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | N/A | N/A | Up |
Historical SBTX trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Shooting Star Candlestick | Bearish | 0.00% | |
New 52 Week High | Strength | 0.00% | |
Upper Bollinger Band Walk | Strength | 0.00% | |
Multiple of Ten Bearish | Other | 0.00% | |
Weak + Overbought | Other | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Weak, Overbought and Reversal Signs | Reversal | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Upper Bollinger Band Touch | Strength | 0.00% | |
New 52 Week Closing High | Bullish | -2.93% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
Down 2 % | about 9 hours ago | |
Down 1% | about 9 hours ago | |
Reversed from Up | about 10 hours ago | |
60 Minute Opening Range Breakdown | about 10 hours ago | |
Up 1 ATR | about 11 hours ago |
Get a Trading Assistant
- Earnings date: ???
Silverback Therapeutics, Inc. Description
Silverback Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Its lead product candidate is SBT6050, which is in a Phase I/Ib clinical trial, a TLR8 agonist linker-payload conjugated to a HER2-directed monoclonal antibody that targets tumors, such as breast, gastric, and non-small cell lung cancers. The company also focuses on developing SBT6290, a product candidate that is in preclinical stage, which is a TLR8 linker-payload conjugated to a monoclonal antibody that targets Nectin4, which is expressed in bladder, triple negative breast, head and neck, and non-small cell lung cancers. In addition, it engages in developing SBT8230, a TLR8 linker-payload conjugated to an ASGR1 monoclonal antibody that is under development for the treatment of chronic hepatitis B virus infection; and agents that localize therapies to modulate pathways in additional oncology and fibrosis indications using TLR8 and other linker-payloads. Silverback Therapeutics, Inc. was founded in 2016 and is headquartered in Seattle, Washington.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Cancer Life Sciences Clinical Medicine Immunology Drugs Treatment Of Cancer Monoclonal Antibody Small Cell Lung Cancer Antibody Hepatitis B Antineoplastic Drugs Tumors Targeted Therapy Serious Diseases Her2 Hepatitis B Virus Fibrosis Linker Lung Cancers Viral Infection Small Cell Lung Cancers Viral Infections Chronic Hepatitis B Virus Hepatitis B Virus Infection Non Small Cell Lung Cancers Tlr8
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 54.41 |
52 Week Low | 24.22 |
Average Volume | 241,578 |
200-Day Moving Average | 0.00 |
50-Day Moving Average | 0.00 |
20-Day Moving Average | 39.52 |
10-Day Moving Average | 43.05 |
Average True Range | 4.42 |
ADX | 44.58 |
+DI | 36.57 |
-DI | 9.36 |
Chandelier Exit (Long, 3 ATRs ) | 41.14 |
Chandelier Exit (Short, 3 ATRs ) | 42.28 |
Upper Bollinger Band | 50.77 |
Lower Bollinger Band | 28.27 |
Percent B (%b) | 0.89 |
BandWidth | 56.93 |
MACD Line | 4.94 |
MACD Signal Line | 3.99 |
MACD Histogram | 0.9521 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 57.64 | ||||
Resistance 3 (R3) | 58.63 | 56.52 | 56.08 | ||
Resistance 2 (R2) | 56.52 | 54.15 | 56.02 | 55.56 | |
Resistance 1 (R1) | 52.42 | 52.68 | 51.37 | 51.43 | 55.05 |
Pivot Point | 50.31 | 50.31 | 49.78 | 49.81 | 50.31 |
Support 1 (S1) | 46.21 | 47.94 | 45.16 | 45.22 | 41.59 |
Support 2 (S2) | 44.10 | 46.47 | 43.60 | 41.08 | |
Support 3 (S3) | 40.00 | 44.10 | 40.56 | ||
Support 4 (S4) | 39.01 |